Skip to content
Sign in

ADPT · NASDAQ

Adaptive Biotechnologies (ADPT) Stock Price & Fundamentals

$735.86+1.15%+$8.39End-of-day price as of Oct 9, 2026

Adaptive Biotechnologies (ADPT) closed at $735.86 on Oct 9, 2026, up 1.15% from the previous close of $727.47.

Share price, past year

1Y +57.46%

52-week range $462.98 – $745.80. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$735.86
Sep 30, 2026$721.71
Aug 31, 2026$729.46
Jul 31, 2026$663.85
Jun 30, 2026$665.24
May 29, 2026$670.79
Apr 30, 2026$619.10
Mar 31, 2026$599.38
Feb 27, 2026$568.24
Jan 30, 2026$554.79
Dec 31, 2025$548.53
Nov 28, 2025$499.35
Oct 31, 2025$472.82

Key statistics

Market cap
$117.05B
P/E (TTM)
—
EPS (TTM)
−$0.40
Revenue (TTM)
$308.08M
Net income (TTM)
−$63.85M
Shares outstanding
159.1M
Dividend yield
—
52-week range
$462.98 – $745.80

Adaptive Biotechnologies's market cap is $117.05B, based on a share price of $735.86 and 159.1M shares outstanding as of Jun 30, 2026.

Financials

Adaptive Biotechnologies reported revenue of $276.98M for fiscal 2025, up 54.77% from fiscal 2024.

Adaptive Biotechnologies reported a net loss of $59.50M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 9 years shown.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Adaptive Biotechnologies annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$276.98M+54.8%−$59.50M−21.5%−$0.39−$48.95M
FY2024ended Dec 31, 2024$178.96M+5.1%−$159.49M−89.1%−$1.08−$98.88M
FY2023ended Dec 31, 2023$170.28M−8.1%−$225.25M−132.3%−$1.56−$167.02M
FY2022ended Dec 31, 2022$185.31M+20.1%−$200.19M−108.0%−$1.40−$200.29M
FY2021ended Dec 31, 2021$154.34M+56.9%−$207.28M−134.3%−$1.48−$254.47M
FY2020ended Dec 31, 2020$98.38M+15.7%−$146.23M−148.6%−$1.11−$168.49M
FY2019ended Dec 31, 2019$85.07M+52.8%−$68.61M−80.7%−$1.01$194.20M
FY2018ended Dec 31, 2018$55.66M+44.8%−$46.45M−83.4%−$3.67−$38.56M
FY2017ended Dec 31, 2017$38.45M—−$42.83M−111.4%−$3.50−$37.28M
Adaptive Biotechnologies quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$71.55M−$39.79M−$0.25
Q1 FY2026ended Mar 31, 2026$70.87M−$20.03M−$0.13
Q4 FY2025ended Dec 31, 2025$71.68M−$13.58M−$0.08
Q3 FY2025ended Sep 30, 2025$93.97M$9.55M$0.06
Q2 FY2025ended Jun 30, 2025$58.88M−$25.61M−$0.17
Q1 FY2025ended Mar 31, 2025$52.44M−$29.85M−$0.20
Q4 FY2024ended Dec 31, 2024$47.46M−$33.69M−$0.22
Q3 FY2024ended Sep 30, 2024$46.44M−$32.07M−$0.22

Company profile

Name
Adaptive Biotechnologies Corp
Ticker
ADPT
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
1165 Eastlake Ave E, Seattle, WA 98109
Incorporated in
WA
Fiscal year ends
December
SEC CIK
0001478320

Recent SEC filings

Frequently asked questions

What is Adaptive Biotechnologies's stock price?

Adaptive Biotechnologies (ADPT) closed at $735.86 on Oct 9, 2026, up 1.15% from the previous close of $727.47.

What is Adaptive Biotechnologies's market cap?

Adaptive Biotechnologies's market cap is $117.05B, based on a share price of $735.86 and 159.1M shares outstanding as of Jun 30, 2026.

How much revenue does Adaptive Biotechnologies make?

Adaptive Biotechnologies reported revenue of $276.98M for fiscal 2025, up 54.77% from fiscal 2024.

Does Adaptive Biotechnologies pay a dividend?

Adaptive Biotechnologies's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Adaptive Biotechnologies Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures